Screener
Pfizer PFE R&D
Discontinued — last reported Q4 '25
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Pfizer’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 12:44 PM EST
- Fiscal year
- FY2025
- Accession
- 0000078003-26-000026
| (MILLIONS, EXCEPT PER SHARE DATA) | Year Ended December 31, 2025 | Year Ended December 31, 2024 | 2023 |
|---|---|---|---|
| Costs and expenses: | |||
| Cost of sales(a), (b) | 16,067 | 17,851 | 24,954 |
| Selling, informational and administrative expenses(a) | 13,794 | 14,730 | 14,771 |
| Research and development expenses(a) | 10,437 | 10,822 | 10,679 |
| Acquired in-process research and development expenses | 1,613 | 108 | 194 |
| Amortization of intangible assets | 4,874 | 5,286 | 4,733 |
| Restructuring charges and certain acquisition-related costs | 1,550 | 2,419 | 2,943 |
| Other (income)/deductions––net | 6,724 | 4,388 | 222 |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Pfizer's R&D?
- Pfizer (PFE) reported R&D of $3.21B in Q4 2025.
- How has Pfizer's R&D changed year-over-year?
- Pfizer's R&D increased by 5.6% year-over-year, from $3.04B to $3.21B.
- What is the long-term trend for Pfizer's R&D?
- Over 4 years (2021 to 2025), Pfizer's R&D has grown at a 0.2% compound annual growth rate (CAGR), from $10.36B to $10.44B.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Pfizer's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude